Mouthwash may tame chemo side effect in breast and lung cancer

NCT ID NCT06974604

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a dexamethasone mouthwash can lower the chance of painful mouth sores (stomatitis) caused by the cancer drug datopotamab deruxtecan. About 60 people with advanced breast or lung cancer will use the mouthwash for the first five days of each treatment cycle. The goal is to reduce mouth sore rates by 20% compared to historical data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dexamethasone mouthwash
What this could lead to
If it works, this could provide a simple way to prevent painful mouth sores in patients receiving this type of chemotherapy, improving their quality of life during treatment.
What could go wrong
This is a small, early-phase trial with only 60 participants and no comparison group, so results may not be definitive. The mouthwash may not reduce sores enough to be clinically meaningful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rhode Island and the Miriam Hospitals (Brown University Health)

    RECRUITING

    Providence, Rhode Island, 02903/02906, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.